Pneumocystis jirovecii pneumonia in systemic lupus erythematosus: a nationwide cohort study in Taiwan.

Wen-Hsiu WangChien-Chih LaiYi-Fan HuangTzu-Hao LiYen-Po TsaoWei-Sheng ChenYu-Sheng Chang

Published in: Arthritis care & research (2021)

Patients with SLE have a considerably high PJP risk. Cyclophosphamide does not increase PJP risk. Male sex, ESRD, MMF use, intravenous steroid pulse therapy, oral prednisolone or equivalent (>7.5 mg/day) are risk factors for PJP, whereas hydroxychloroquine use reduces PJP risk.

Keyphrases

low dose
intensive care unit
mesenchymal stem cells
chronic kidney disease
acute respiratory distress syndrome
end stage renal disease